Skip to main content
TipRanks
Go Ultimate75% OFF

Corbus Pharmaceuticals (3371) Stock Price & Analysis

0 Followers

3371 Stock Chart & Stats

€2.75-€0.55(-16.55%)
At close: 5:30 PM GMT+1
€4€6€8Aug 17Sep 17Oct 8Nov 16
Day’s Range
EUR 2.75 - EUR 2.75
52-Week Range
EUR 2.23 - EUR 11.26
Previous Close
EUR 3.30
Volume
N/A
Average Volume (3M)
17
Market Cap
EUR 56.54M
Enterprise Value
EUR 30.69M
Total Cash (Recent Filing)
EUR 115.34M
Total Debt (Recent Filing)
EUR 3.91M
Price to Earnings (P/E)
―
Beta
0.95
Next Earnings
Mar 15, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Positive Obesity-program Efficacy And Tolerability

CRB-913 is producing clinically meaningful weight loss across tested doses while maintaining a reported tolerability profile, supporting continued development of Corbus’s oral, non-incretin obesity approach. These results could broaden the pipeline’s strategic value if replicated in later-stage studies.

Progress Toward Pivotal Oncology Development

Advancing TEMPO-1 into Phase 3 represents a meaningful transition from earlier clinical work toward a potentially registrational oncology program. The study’s defined efficacy endpoints and FDA-cleared design provide a clearer development pathway and could improve the pipeline’s maturity over the next several quarters.

Low Financial Leverage

Very low debt reduces interest and repayment pressure relative to a more leveraged biotechnology company, preserving flexibility for research and clinical spending. Although the capital base has declined, limited borrowing obligations remain a structural balance-sheet advantage while Corbus advances its pipeline.

Bears Say

Pre-revenue Model With Widening Losses

Corbus has not yet established product revenue, while losses have expanded sharply as development spending continues. This combination leaves operating performance dependent on successful clinical progress and eventual commercialization, increasing the financial consequences of delays or unsuccessful programs.

Persistent And Worsening Cash Burn

Large negative operating and free cash flow means Corbus is consuming capital rather than funding development internally. Continued outflows can require additional financing and may constrain investment choices, while the link between free cash flow and net loss indicates the losses are translating into real cash usage.

Pipeline Remains Dependent On Clinical Execution

The company’s value remains tied to drug candidates that are still in clinical development rather than established commercial products. Progression through trials, regulatory review, and eventual approval is therefore essential, leaving future operating improvement dependent on execution across multiple development stages.

Corbus Pharmaceuticals News

3371 FAQ

What was Corbus Pharmaceuticals’s price range in the past 12 months?
Corbus Pharmaceuticals lowest stock price was €2.23 and its highest was €11.26 in the past 12 months.
What is Corbus Pharmaceuticals’s market cap?
Corbus Pharmaceuticals’s market cap is €56.54M.
When is Corbus Pharmaceuticals’s upcoming earnings report date?
Corbus Pharmaceuticals’s next earnings report is estimated for Mar 15, 2027 (not yet confirmed), which is in 116 days.
How were Corbus Pharmaceuticals’s earnings last quarter?
Corbus Pharmaceuticals released its earnings results on Nov 10, 2026. The company reported -€1.642 earnings per share for the quarter, missing the consensus estimate of -€1.155 by -€0.487.
Is Corbus Pharmaceuticals overvalued?
According to Wall Street analysts Corbus Pharmaceuticals’s price is currently Undervalued.
Does Corbus Pharmaceuticals pay dividends?
Corbus Pharmaceuticals does not currently pay dividends.
What is Corbus Pharmaceuticals’s EPS estimate?
Corbus Pharmaceuticals’s EPS estimate is -1.24.
How many shares outstanding does Corbus Pharmaceuticals have?
Corbus Pharmaceuticals has 20,606,760 shares outstanding.
What happened to Corbus Pharmaceuticals’s price movement after its last earnings report?
Corbus Pharmaceuticals reported an EPS of -€1.642 in its last earnings report, missing expectations of -€1.155. Following the earnings report the stock price went up 30.657%.
Which hedge fund is a major shareholder of Corbus Pharmaceuticals?
Hedge funds hold Corbus Pharmaceuticals shares: the largest hedge-fund position in Corbus Pharmaceuticals is 1,948,387,372 shares, and hedge funds increased their holdings by 39.0K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology